Donald School Journal of Ultrasound in Obstetrics and Gynecology

Register      Login

VOLUME 4 , ISSUE 2 ( April-June, 2010 ) > List of Articles

REVIEW ARTICLE

First Trimester Ultrasound Screening: An Update

JD Sonek, M Glover, M Zhou, KH Nicolaides

Keywords : First trimester screening,nuchal translucency,nasal bone,frontomaxillary angle,ductus venosus,tricuspid valve,intracranial translucency,uterine artery

Citation Information : Sonek J, Glover M, Zhou M, Nicolaides K. First Trimester Ultrasound Screening: An Update. Donald School J Ultrasound Obstet Gynecol 2010; 4 (2):97-116.

DOI: 10.5005/jp-journals-10009-1133

License: CC BY-NC 4.0

Published Online: 01-06-2010

Copyright Statement:  Copyright © 2010; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

For many years, the main use of ultrasound in the first trimester of pregnancy was to confirm viability and to establish gestational age. Indeed, the crown-rump length measurement in the first trimester remains the most accurate method to estimate the gestational age even today. However, improvements in ultrasound equipment and improvement in our understanding of normal and abnormal fetal development allows us now to perform a much more complete first trimester fetal evaluation. This pertains not only to the diagnosis of fetal anomalies but also to screening for fetal defects. The combination of the nuchal translucency measurement and maternal serum biochemistries (free β-hCG and PAPP-A) has been shown to be an extremely efficient way to screen for fetal aneuploidy. The addition of other first trimester markers such as the nasal bone evaluation, frontomaxillary facial angle measurement, and Doppler evaluation of blood flow across the tricuspid valve and through the ductus venosus improves the screening performance even further by increasing the detection rates and decreasing the false positive rates. Several of the first trimester markers also are useful in screening for cardiac defects. Furthermore, significant nuchal translucency thickening has been associated with a variety of genetic and nongenetic syndromes. A recently described first trimester marker called the intracerebral translucency appears to hold great promise in screening for open spine defects. Finally, it appears that a first trimester evaluation (uterine artery Doppler and the measurement of certain biochemical markers in the maternal serum) significantly improves the assessment of the risk of preeclampsia.


PDF Share
  1. Observations on an ethnic classification of idiots. Clin Lectures and Reports, London Hospital 1866;3:259-62.
  2. Screening for trisomies 21,18 and 13 by maternal age, fetal nuchal translucency, fetal heart rate free beta-hCG and pregnancy-associated plasma protein-A. Human Reprod. Sep;23:1968-57. Epub 2008 June 10.
  3. Fetal nasal bone in screening for trisomy 21, 18, 13 and Turner syndrome at 11-13 weeks of gestation. Ultrasound in Obstet Gynecol 2009;33: 259-64.
  4. Frontomaxillary facial angle in screening for trisomy 21 at 11+0 to 13+6 weeks. Ultrasound Obstet Gynecol 2008;32:5-11.
  5. Down syndrome: A cardiovascular perspective. J Intellect Disabil Res 2009;53:419-25. Epub 2009 Feb 18.
  6. Increased cardiac muscle size and reduced cell number in Down syndrome. Pediatric Pathol. 1986;6:47-53.
  7. Collagen type VI expression during cardiac development and in human fetuses with trisomy 21. Anat Rec 2003;275A:1109-16.
  8. Collagen XVIII/endostatin is associated with the epithelial-mesenchymal transformation in the atrioventricular valves during cardiac development. Dev Dynamics 2006;235:132-42.
  9. Tricuspid regurgitation in the diagnosis of chromosomal anomalies in the fetus at 11-14 weeks of gestation. Heart 2003;89:1071-73.
  10. Likelihood ratio for trisomy 21 in fetuses with tricuspid regurgitation at the 11 to 13+6 week scan. Ultrasound Obstet Gynecol 2005;26:22-27.
  11. Tricuspid regurgitation in screening for trisomies 21, 18 and 13 and Turner syndrome at 11+0 to 13+6 weeks of gestation. Ultrasound Obstet Gynecol 2009;33:18-22.
  12. Screening for adverse pregnancy outcome by ductus vensous Doppler at 11-13+6 weeks of gestation. Obstet Gynecol 2008;112:598-605.
  13. Screening for aneuploidy in the first trimester by assessment of blood flow in the ductus venosus. Br J Obstet Gynaecol 2002;109:1015-19.
  14. Application of ductus venosus Doppler elocimetry for the detection of fetal aneuploidy in the first trimester of pregnancy. Fetal Diagn Ther 2002;1: 308-14.
  15. First-trimester ductus venosus velocimetry in relation to nuchal translucency thickness and fetal karyotype. Fetal Diagn Ther 2002;17:52-57.
  16. Ductus venosus assessment at the time of nuchal translucency measurement in the detection of fetal aneuploidy. Prenat Diagn 2003;23: 921-26.
  17. Ductus venosus Doppler in screening for trisomies 21, 18, and 13 and Turner syndrome at 11-13 weeks of gestation. Ultrasound Obstet Gynecol 2009;33:512-17.
  18. Ductus venosus studies in fetuses at high risk for chromosomal or heart abnormalities: Relationship with nuchal translucency measurement and fetal outcome. Ultrasound Obstet Gynecol 2001; 17:288-94.
  19. Ductus venosus Doppler in fetuses with cardiac defects and increased nuchal translucency thickness. Ultrasound Obstet Gynecol 2008;31:256-60.
  20. Fetal heart rate in chromosomally abnormal fetuses. Ultrasound Obstet Gynecol 2000;16:610-13.
  21. A screening program for trisomy 21 at 10 to 14 weeks using fetal nuchal translucency, maternal serum free ß-human chorionic gonadotropin and pregnancy-associated plasma protein-A. Ultrasound Obstet Gynecol 1999;13:231-37.
  22. Aneuploidy screening in the first trimester. Am J Med Genet Part C Semin Med Genet. 2007;145C:18-32.
  23. Frontomaxillary facial angle in fetuses with trisomy 13 at 11+0 to 13+6 weeks. Ultrasound Obstet Gynecol 2007;30:819-23.
  24. Frontomaxillary and mandibulomaxillary facial angles at 11+0 to 13+6 weeks in fetuses with trisomy 18. Ultrasound Obstet Gynecol 2007; 30:928-33.
  25. Assessment of intracranial translucency (IT) in the detection of spina bifida at the 11-13 week scan. Ultrasound Obstet Gynecol 2009;34: 249-52.
  26. Maternal risk factors for hypertensive disorders in pregnancy: A multivariate approach. J Hum Hypertens. 2010;24:104-10.
  27. Hypertensive disorders in pregnancy: Screening by uterine artery Doppler at 11-13 weeks. Ultrasound Obstet Gynecol 2009;34:142-48.
  28. Hypertensive disorders in pregnancy: Combined screening by uterine Doppler, blood pressure and serum PAPP-A at 11-13 weeks. Prenat Diagn Epub 2010 Jan 27.
  29. Hypertensive disorders in pregnancy: Screening by uterine artery Doppler and blood pressure at 11-13 weeks. Ultrasound Obstet Gynecol 2009;34:487-502.
  30. Down syndrome screening in the first and/or second trimester: Model predicted performance using meta-analysis parameters. Semin Perinatol 2005;29:252-57.
  31. Abnormalities of the heart and great arteries in chromosomally normal fetuses with increased nuchal translucency thickness at 11-13 weeks of gestation. Ultrasound Obstet Gynecol 1996;7:245-50.
  32. Screening for fetal aneuploidies and fetal cardiac abnormalities by nuchal translucency thickness measurement at 10-14 weeks of gestation as part of routine antenatal care in an unselected population. Br J Obstet Gynaecol 1999;106:1029-34.
  33. Elevated firsttrimester nuchal translucency increases the risk of congenital heart defects. Am J Obstet Gynecol 2005;192:1357-61.
  34. Nuchal translucency: A marker for the antenatal diagnosis of aortic coarctation. Br J Obstet Gynaecol 1996;103:1044-45.
  35. Increased nuchal translucency at 10-14 weeks of gestation as a marker for major cardiac defects. Ultrasound Obstet Gynecol 1997;10:242-46.
  36. Early diagnosis of major cardiac defects in chromosomally normal fetuses with increased nuchal translucency. Br J Obstet Gynaecol 1999;106:829-33.
  37. Incidence of major structural cardiac defects associated with increased nuchal translucency but normal karyotype. Ultrasound Obstet Gynecol 2001;18: 610-14.
  38. Structural and functional cardiac abnormalities identified prior to 16 weeks’ gestation in fetuses with increased nuchal translucency. Ultrasound Obstet Gynecol 2003;22:470-78.
  39. Cardiac defects in chromosomally normal fetuses with increased nuchal translucency at 10-14 weeks of gestation. J Matern Fetal Neonatal Med 2003;13:163-70.
  40. Fetal cardiac defects and increased nuchal translucency thickness. Am J Obstet Gynecol 2003;189, Abstract 571.
  41. Using fetal nuchal translucency to screen for major congenital cardiac defects at 10-14 weeks of gestation: Population based cohort study. British Medical Journal 1999;318:81-85.
  42. Limitations of using first trimester nuchal translucency measurement in routine screening for major congenital heart defects. Ultrasound Obstet Gynecol 2001;17:106-10.
  43. Increased nuchal translucency and congenital heart defects in euploid fetuses. The Szeged experience. Eur J Obstet Gynecol Reprod Biol 2002;101:124-28.
  44. Increased nuchal translucency and congenital heart defects in a low-risk population. Prenat Diagn 2003;23:985-89.
  45. Screening performance of first-trimester nuchal translucency for major cardiac defects: A meta-analysis. Am J Obstet Gynecol 2003;189:1330-35.
  46. Abnormalities of the heart and great arteries in chromosomally normal fetuses with increased nuchal translucency thickness at 11-13 weeks of gestation. Ultrasound Obstet Gynecol 1996;7:245-50.
  47. Omphaloceleexstrophy- imperforate anus-spinal defects (OEIS) complex associated with increased nuchal translucency. Ultrasound Obstet Gynecol 2003;22:95-97.
  48. Fetal nuchal translucency thickness at 10-14 weeks of gestation and congenital diaphragmatic hernia. Obstet Gynecol 1997;90:943-47.
  49. Prenatal ultrasound diagnosis and management of body stalk anomaly: Analysis of nine singleton and two multiple pregnancies. Ultrasound Obstet Gynecol 2003;21:322-28.
  50. Sirenomelia sequence: First-trimester diagnosis with both two- and threedimensional sonography. Ultrasound Med 2002;21:915-20.
  51. Defects and syndromes in chromosomally normal fetuses with increased nuchal translucency at 10-14 weeks of gestation. Ultrasound Obstet Gynecol 1998;11:391-400.
  52. Increased nuchal translucency with normal karyotype. In Sebire NJ, Snijders RJM, Nicolaides KH (Eds). The 11-14 week scan: Diagnosis of fetal abnormalities. Carnforth, UK: Parthenon Publishing; 1999;67-88.
  53. Increased nuchal translucency with normal karyotype. Am J Obstet Gynecol April 2005;192:1005-21.
  54. Increased nuchal translucency is associated with asphyxiating thoracic dysplasia. Ultrasound Obstet Gynecol 1997;10:297-98.
  55. Achondrogenesis type 2 diagnosed by transvaginal ultrasound at 12 weeks of gestation. Prenat Diagn 1993;13:523-28.
  56. Osteogenesis imperfecta and other skeletal dysplasias presenting with increased nuchal translucency in the first trimester. Am J Med Genet 2001;98:117-20.
  57. Transvaginal ultrasound recognition of nuchal oedema in the first-trimester diagnosis of achondrogenesis. J Clin Ultrasound 1991;19:586-90.
  58. Achondrogenesis type I diagnosed by transvaginal ultrasonography at 13 weeks’ gestation. Am J Obstet Gynecol 1995;173:1620-22.
  59. First trimester diagnosis of Blomstrand lethal osteochondrodysplasia. Am J Med Genet 1997;73:345-50.
  60. Hypophosphatasia associated with increased nuchal translucency: A report of three consecutive pregnancies. Ultrasound Obstet Gynecol 2002; 20:294-95.
  61. Early sonographic diagnosis of Jarcho-Levin syndrome: A prospective screening program in one family. Ultrasound Obstet Gynecol 1997;9:314-18.
  62. Upper limb phocomelia associated with increased nuchal translucency in a monochorionic twin pregnancy J Ultrasound Med 2002;21:355-60.
  63. Prenatal diagnosis of pseudothalidomide syndrome in consecutive pregnancies of a consanguineous couple. Ultrasound Obstet Gynecol 1997; 10:4252-28.
  64. First-trimester diagnosis of Robinow syndrome. Fetal Diagn Ther 2001;16:308-11.
  65. Transvaginal sonographic diagnosis of shortrib polydactyly dysplasia at 13 weeks’ gestation. Prenat Diagn 1998;18:1198-201.
  66. Noonan syndrome: A cryptic condition in early gestation. Am J Med Genet 2000;92:159-65.
  67. Congenital lymphedema presenting with increased nuchal translucency at 13 weeks of gestation. Prenat Diagn 2002;22:91-92.
  68. Increased first-trimester nuchal translucency as a prenatal manifestation of salt-wasting congenital adrenal hyperplasia. Ultrasound Obstet Gynecol 2002;20:392-94.
  69. Congenital nephrotic syndrome presenting with increased nuchal translucency in the first trimester. Prenat Diagn 2002;22:93-95.
  70. Lethal congenital arthrogryposis presents with increased nuchal translucency at 10–14 weeks of gestation. Ultrasound Obstet Gynecol 1997;9:310-13.
  71. Sonographic and maternal serum screening abnormalities in fetuses affected by spinal muscular atrophy. Prenat Diagn 1997;17:166-69.
  72. The association of spinal muscular atrophy type II and increased nuchal translucency. Ultrasound Obstet Gynecol 2002;19:312-13.
  73. Nuchal translucency in fetuses affected by homozygous a-thalassemia-1 at 12-13 weeks of gestation. Ultrasound Obstet Gynecol 1999;13:238-40.
  74. Blackfan-Diamond anemia and dyserythropoietic anemia presenting with increased nuchal translucency at 12 weeks of gestation. Ultrasound Obstet Gynecol 2002;20:197-99.
  75. Congenital erythropoietic porphyria (Gunther's disease): Two cases with very early prenatal manifestation and cystic hydroma. Prenat Diagn 2003;23: 25-30.
  76. Fanconi anemia associated with increased nuchal translucency detected by first-trimester ultrasound. Ultrasound Obstet Gynecol 2001;17:160-62.
  77. Fetal hydrops secondary to human parvovirus infection in early pregnancy. Prenat Diagn 1996;16:342-44.
  78. Parvoviral infection associated with increased nuchal translucency: A case report. J Perinatol 2000;20:129-31.
  79. Fetal hydrops in the first trimester associated with maternal parvovirus infection. J Clin Ultrasound 1998;26:314-16.
  80. Detailed screening for fetal anomalies and cardiac defects at the 11-13 week scan. Ultrasound Obstet Gynecol 2006;27:613-18.
  81. Abdominal ultrasound examination of the first trimester fetus. Am J Obstet Gynecol 1988;159: 165-75.
  82. First trimester transvaginal sonographic diagnosis of fetal anomalies. Lancet 1989;1:444-45
  83. The role of transvaginal sonography in the early detection of congenital heart disease. Ultrasound Obstet Gynecol 1992;2:248-51.
  84. Assessment of fetal anatomy at 12 to 13 weeks of gestation by transabdominal and transvaginal sonography. Br J Obstet Gynaecol 1996;103: 82-85.
  85. Screening for fetal anomalies in the 12th week of pregnancy by transvaginal sonography in an unselected population. Prenat Diagn 1997;17:753-59.
  86. First trimester ultrasonographic diagnosis of fetal structural abnormalities in a low risk population. Br J Obstet Gynaecol 1998;105:53-57.
  87. Detection of fetal structural abnormalities at the 11-14 week ultrasound scan. Prenat Diagn 2002;22:1-4.
  88. Screening for major structural abnormalities at the 11- to 14-week ultrasound scan. Am J Obstet Gynecol 2006;194:393-96.
  89. Early diagnosis of fetal congenital heart disease by transvaginal echocardiography. Ultrasound Obstet Gynecol 1993;3:310-17.
  90. First-trimester diagnosis of fetal congenital heart disease by transvaginal ultrasonography. Obstet Gynecol 1994;84:69-72.
  91. The evaluation of cardiac biometry in major cardiac defects detected in early pregnancy. Arch Gynecol Obstet 2003;268:94-101.
  92. Estimation of gestational age by transvaginal sonographic measurements of greatest embryonic length in dated human embryos. Ultrasound Obstet Gynecol 1994;4:457-62.
  93. Early and simple determination of chorionic and amniotic type in multifetal gestations in the first 14 weeks by high frequency transvaginal ultrasound. Am J Obstet Gynecol 1994;170:824-29.
  94. The lambda sign at 10-14 weeks of gestation as a predictor of chorionicity in twin pregnancies. Ultrasound Obstet Gynecol 1996;7:421-23.
  95. Evolution of the lambda or twin/chorionic peak sign in dichorionic twin pregnancies. Obstet Gynecol 1997;89:439-41.
  96. Maternal serum free beta-hCG at 10 to 14 weeks in trisomic twin pregnancies. Br J Obstet Gynaecol 1997;104:741-43.
  97. Screening for trisomy 21 in twin pregnancies in the first trimester using free beta-hCG and PAPP-A, combined with fetal nuchal translucency thickness. Prenat Diagn 2000;20: 91-95.
  98. Screening for trisomy 21 in twins using first trimester ultrasound and maternal serum biochemistry in a one-stop clinic: A review of three years experience. BJOG 2003;110:276-80.
  99. Discordance in nuchal translucency thickness in the prediction of severe twin-to-twin transfusion syndrome. Ultrasound Obstet Gynecol 2007;29:527-32.
  100. Ductus venosus Doppler at 11 to 13 weeks of gestation in the prediction of outcome in twin pregnancies. Obstet Gynecol 2009;113:860-65.
  101. Assessment of fetal anatomy at the 11-14 week ultrasound examination. 2004; 24:730-34.
  102. Firsttrimester sonography of physiological midgut herniation and early diagnosis of omphalocele. Prenat Diagn 1997;17:511-18.
  103. Fetal exomphalos and chromosomal defects: Relationship to maternal age and gestation. Ultrasound Obstet Gynecol 1995;6:250-55.
  104. Firsttrimester sonography of physiological midgut herniation and early diagnosis of omphalocele. Prenat Diagn 1997;17:511-18.
  105. Ultrasound screening for anecephaly at 10-14 weeks of gestation. Ultrasound Obstet Gynecol 1997;9:14-16.
  106. The prenatal development of the human nasal and vomeral bones. J Craniofac Genet Dev Biol 1994;14:124-34.
  107. Human fetal cardiac function during the first trimester of pregnancy. Heart 2005;91:443-48.
  108. A mixture model of nuchal translucency thickness in screening for chromosomal defects. Ultrasound Obstet Gynecol. 2008;31:376-83.
  109. The optimal gestational age to examine fetal anatomy and measure nuchal translucency in the first trimester. Ultrasound Obstet Gynecol 1998;11:258-61.
  110. Optimizing the timing for nuchal translucency measurement. Prenat Diagn 2002;22: 775-77.
  111. Fetal nuchal translucency: Ultrasound screening for fetal trisomy in the first trimester. Br J Obstet Gynaecol 1994;101:782-86.
  112. Risk of recurrence of fetal chromosomal aberration: Analysis of trisomy 21, trisomy 18, trisomy 13, and 45 X, in 1,076 Japanese mothers. J Obstet Gynaecol Res 1999;25:373-79.
  113. Fetal nuchal translucency: Ultrasound screening for chromosomal defects in first trimester of pregnancy. Br Med J 1992;304:867-89.
  114. Nuchal translucency and congenital heart defects: Heart failure or not? Ultrasound Obstet Gynecol 2000;16:30-36.
  115. Abnormal cardiac function in fetuses with increased nuchal translucency. Ultrasound Obstet Gynecol 2003;21:539-42.
  116. Cardiac gene expression of atrial natriuretic peptide and brain natriuretic peptide in trisomic fetuses. Obstet Gynecol 1996;87:506-10.
  117. Atrial natriuretic peptide distribution in fetal and failed adult human hearts. Circulation 1988;78:920-27.
  118. Morphological classification of nuchal skin in fetuses with trisomy 21, 18 and 13 at 12-18 weeks and in a trisomy 16 mouse. Anat Embryol 1998;197:105-24.
  119. Collagen type VI gene expression in the skin of trisomy 21 fetuses. Obstet Gynecol 1998;91:319-23.
  120. Hyaluronan in the nuchal skin of chromosomally abnormal fetuses. Hum Reprod 2000;15:1155-58.
  121. Lymphatic abnormalities in fetuses with posterior cervical cystic hygroma. Am J Med Genet 1989;33:352-56
  122. Lymphatic vessel hypoplasia in fetuses with Turner syndrome. Hum Reprod 1999;14:823.
  123. Fetoscopy in the assessment of unexplained fetal hydrops. Br J Obstet Gynaecol 1985;92:671-79.
  124. Parvovirus as a differential diagnosis of hydrops fetalis in the first trimester. Fetal Diagn Ther 2000;15:234-36.
  125. Nuchal translucency measurements: Frequency, distribution, and changes with gestation in a general population. Br J Obstet Gynaecol 1996;103:1201-04.
  126. The effect of fetal neck position on nuchal translucency measurement at 10- 14 weeks. Br J Obstet Gynaecol 1998;105:872-76.
  127. The effect of nuchal cord on nuchal translucency measurement at 10-14 weeks. Ultrasound Obstet Gynecol 1998;11:271-73.
  128. Cystic hygromas, nuchal edema, and nuchal translucency at 11-14 weeks of gestation. Obstet. Gynecol 2006;107:678-83.
  129. for the FASTER Trial Research Consortium. First Trimester Septated Cystic Hygroma: Prevalence, Natural History, and Pediatric Outcome. Obstet Gynecol 2005;106:288-94.
  130. Letter to the Editor, Obstet Gynecol 2006;107:424.
  131. For the FASTER Research Consortium. Is there a nuchal translucency millimeter measurement above which there is no added benefit from first trimester serum screening? Am J Obstet Gynecol 2006;195:843-47.
  132. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal translucency thickness at 10-14 weeks of gestation. Lancet 1998;351:343-46.
  133. Correlation between nuchal thickness and abnormal karyotype in first trimester fetuses. Med J Aust 1996;165:365-68.
  134. First-trimester ultrasound screening for chromosomal defects. Ultrasound Obstet Gynecol. 1996;7:216-26.
  135. Screening for Down's syndrome by fetal nuchal translucency measurement in a general obstetric population. Ultrasound Obstet Gynecol 1998;12: 163-69.
  136. Screening for chromosomal abnormalities in the first trimester using ultrasound and maternal serum biochemistry and in a one-stop clinic: A review of three years prospective experience. Br J Obstet Gynaecol 2003;110:281-86.
  137. Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta human chorionic gonadotropin and pregnancy-associated plasma protein-A. Ultrasound Obstet Gynecol 2008;31:618-24.
  138. Prospective validation of first-trimester combined screening for trisomy 21. Ultrasound Obstet Gynecol 2009;34:14-18.
  139. Multicenter study of first-trimester screening for trisomy 21 in 75 821 pregnancies: Results and estimation of the potential impact of individual riskorientated two-stage first-trimester screening. Ultrasound Obstet Gynecol 2005;25:221-26.
  140. Prospective firsttrimester screening for trisomy 21 in 30,564 pregnancies. Am J Obstet Gynecol 2005;192:1761-67.
  141. Screening for triploidy by the risk algorithms for trisomies 21, 18 and 13 at 11-13weeks and 6 days of gestation. Prenat Diagn 2008;28: 1209-13.
  142. Screening for trisomy 18 by maternal age, fetal nuchal translucency, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A. Ultrasound Obstet Gynecol 2008;4:488-92.
  143. Surface anatomy of the face in Down's syndrome: Linear and angular measurements in the craniofacial regions. J Craniofac Surg 2001;12:373-79.
  144. Pattern of malformation in the axial skeleton in human trisomy 21 fetuses. Am J Med Genet 1997;68:466-71.
  145. Skeletal abnormalities in fetuses with Down's syndrome: A radiologic postmortem study. Pediatr Radiol 1999;29:682-88.
  146. A histological and radiological investigation of the nasal bone in fetuses with Down syndrome. Ultrasound Obstet Gynecol 2003;22:22-26.
  147. The nasal bone in fetuses with trisomy 21: Sonographic versus pathomorphological findings. Ultrasound Obstet Gynecol 2003;22:16-21.
  148. Nasal bone assessment in prenatal screening for trisomy 21. Am J Obstet Gynecol 2006;195:1219-30.
  149. Prenatal ultrasonographic diagnosis of nasal bone abnormalities in three fetuses with Down syndrome. Am J Obstet Gynecol 2002;186:139-41.
  150. Nasal bone length in trisomy 18, triploidy and Turner syndrome analyzed on postmortem radiographs. (letter to the editor) Ultrasound Obstet Gynecol 2009;34:605-08.
  151. Absence of nasal bone in fetuses with Trisomy 21 at 11-14 weeks of gestation: An observational study. Lancet 2001;358:1665-67.
  152. Association between first trimester absence of fetal nasal bone on ultrasound and Down's syndrome. Prenat Diagn 2002;22:930-32.
  153. Absence of fetal nasal bone and aneuploidies at first-trimester nuchal translucency screening in unselected pregnancies. Prenat Diagn 2003;23:496-500.
  154. Ultrasound evaluation of fetal nasal bone at 11 to 14 weeks in a consecutive series of 1906 fetuses. Prenat Diagn 2003;23:784-87.
  155. Nasal bone hypoplasia: Is it a common finding amongst chromosomally normal fetuses of southern Chinese women? Gynecol Obstet Invest 2003;56: 99-101.
  156. Absent nasal bone at 11-14 weeks of gestation and chromosomal defects. Ultrasound Obstet Gynecol 2003;22:31-35.
  157. Fetal nasal bone length in chromosomally normal and abnormal fetuses at 11-14 weeks of gestation. J Matern Fetal Neonatal Med 2002;11:400-02.
  158. Assessment of the fetal nasal bone at 11-14 weeks of gestation by three-dimensional ultrasound. Ultrasound Obstet Gynecol 2004;23:232-36.
  159. Likelihood ratio for Trisomy 21 in fetuses with absent nasal bone at the 11-14 weeks scan. Ultrasound Obstet Gynecol 2004;23:218-23.
  160. Integrated ultrasound and biochemical screening for trisomy 21 using nuchal translucency, absent fetal nasal bone, free beta-hCG, and PAPPA at 11 to 14 weeks of gestation. Prenat Diagn 2003;23:306-10.
  161. Nasal bone assessment in prenatal screening for trisomy 21. Am J Obstet Gynecol 2006;195:109-14.
  162. Frontomaxillary facial angle in fetuses with trisomy 21 at 11-13 (+6) weeks’. Am J Obstet Gynecol 2007;196(3):271.e1-4.
  163. Frontomaxillary facial angle at 11+0 to 13+6 weeks: Effect of plane of acquisition. Ultrasound Obstet Gynecol 2007;29:660-65.
  164. Frontomaxillary facial angles in screening for trisomy 21 at 14-23 weeks’ gestation. Am J Obstet Gynecol 2007;197:160.e1-5
  165. Frontomaxillary facial angle in chromosomally normal fetuses at 11+0 to 13+6 weeks. Ultrasound Obstet Gynecol 2007;30:737-41.
  166. Frontomaxillary facial angle in fetuses with trisomy 13 at 11+0 to 13+6 weeks. Ultrasound Obstet Gynecol 2007;30:819-23.
  167. Frontomaxillary and mandibulomaxillary facial angles at 11+0 to 13+6 weeks in fetuses with trisomy 18. Ultrasound Obstet Gynecol 2007; 30:928-33.
  168. Screening for trisomy 21 by tricuspid regurgitation, nuchal translucency and maternal serum free â-hCG and PAPP-A at 11+0 to 13+6 weeks. Ultrasound Obstet Gynecol 2006;27:151-55.
  169. The role of ductus venosus blood flow assessment in screening for chromosomal abnormalities at 10-16 weeks of gestation. Ultrasound Obstet Gynecol 2001;17:295-300.
  170. Ductus venosus blood velocity and the umbilical circulation in the seriously growthretarded fetus. Ultrasound Obstet Gynecol 1994;4:109-14.
  171. Assessment of fetal compromise by Doppler ultrasound investigation of the fetal circulation: Arterial, intracardiac, and venous blood flow velocity studies. Circulation 1995;91:129-38.
  172. Doppler studies of the fetal circulation in twin-twin transfusion syndrome. Ultrasound Obstet Gynecol. 1995; 5:318-24.
  173. Transient increase in nuchal translucency thickness and reversed end-diastolic ductus venosus flow in a fetus with trisomy 18. Ultrasound Obstet Gynecol. 1997;10:397-99.
  174. Ductus venosus revisited: A Doppler blood flow evaluation in the first trimester of pregnancy. Ultrasound in Med and Biol. 1997;23:171-76.
  175. In a different vein: The ductus venosus could yield much valuable information. Ultrasound Obstet Gynecol 1997;9:369-72.
  176. Abnormal ductus venosus blood flow in trisomy 21 fetuses during early pregnancy. Am J Obstet Gynecol. 1999;179:1612-17.
  177. Screening for chromosomal abnormalities at 10-14 weeks: The role of ductus venosus blood flow. Ultrasound Obstet Gynecol 1998;12:380-84.
  178. Anomalous fetal venous return associated with major chormosomopathies in the late first trimester of pregnancy. Ultrasound Obstet Gynecol. 1998;11:209-13.
  179. Cardiac defects in chromosomally normal fetuses with abnormal ductus venosus blood flow at 10-14 weeks. Ultrasound Obstet Gynecol 1999;14:307-10.
  180. Haemodynamic evaluation of the first trimester fetus with special emphasis on venous return. Hum Reprod Update. 2000;6:177-89.
  181. Search for hemodynamic compromise at 11-14 weeks in monochorionic twin pregnancy: Is abnormal flow in the ductus venosus predictive of twin-twin transfusion syndrome. J Matern Fetal Neonatal Med 2005;18: 79-86.
  182. Nuchal translucency measurement: Training of potential examiners. Ultrasound Obstet Gynecol 1996;8:192-95.
  183. Learning curve for sonographic examination of the fetal nasal bone at 11-14 weeks. Ultrasound Obstet Gynecol 2003;22:135-37.
  184. Learning curve for Doppler assessment of ductus venosus flow at 11-13+6 weeks’ gestation. Ultrasound Obstet Gynecol 2008;31:503-06.
  185. Choroid plexus cyst, intracranial echogenic focus, hyperechoic bowel and hydronephrosis in screening for trisomy 21 at 11+0 to 13+6 weeks. Ultrasound Obstet Gynecol. 2008;31:132-35.
  186. Ultrasonographically detectable markers of fetal chromosomal abnormalities. Lancet 1992;340:704-07.
  187. Megacystis at 10-14 weeks of gestation: Chromosomal defects and outcome according to bladder length. Ultrasound Obstet Gynecol 2003;21:338-41.
  188. Fetal megacystis at 10-14 weeks of gestation. Ultrasound Obstet Gynecol 1996;8:387-90.
  189. Megacystis at 10-14 weeks of gestation: Chromosomal defects and outcome according to bladder length. Ultrasound Obstet Gynecol 2003;21:338-41.
  190. First-trimester diagnosis of nuchal anomalies: Significance and fetal outcome. Ultrasound Obstet Gynecol 1992;2:314-16.
  191. Outcome of chromosomally normal live births with increased fetal nuchal translucency at 10-14 weeks’ gestation. J Med Genet 1998;35:222-24.
  192. Outcome of pregnancy in chromosomally normal fetuses with increased nuchal translucency in the first trimester. Ultrasound Obstet Gynecol 2001;18:9-17.
  193. Pregnancy outcome and prognosis in fetuses with increased first-trimester nuchal translucency. Fetal Diagn Ther 2001;16:360-63.
  194. Outcome of fetuses with enlarged nuchal translucency and normal karyotype. Ultrasound Obstet Gynecol 1998;11:401-06.
  195. Nuchal translucency measurement and pregnancy outcome in karyotypically normal fetuses. Ultrasound Obstet Gynecol 2001;17:102-05.
  196. Clinical course and outcome of fetuses with isolated cystic nuchal lesions and normal karyotypes detected in the first trimester. Am J Obstet Gynecol 1994;171:1278-81.
  197. Pregnancy outcomes with increased nuchal translucency after routine Down syndrome screening. Int J Gynaecol Obstet 2004;84:5-9.
  198. Pregnancy outcome in fetuses with increased nuchal translucency and normal karyotype. Prenat Diagn 2002;22:345-49.
  199. Fetal outcome in nuchal translucency with emphasis on normal fetal karyotype. Prenat Diagn 1996;16:537-41.
  200. Nuchal translucency measurement and pregnancy outcome in karyotypically normal fetuses. Ultrasound Obstet Gynecol. 2001;17:102-05.
  201. Outcome of pregnancy in chromosomally normal fetuses with increased nuchal translucency at 10-14 weeks of gestation. Ultrasound Obstet Gynecol. 2001;18:9-17.
  202. Nuchal translucency and fetal cardiac defects: A pooled analysis of major fetal echocardiography centers. Am J Obstet Gynecol 2005;192:89-85.
  203. First trimester transabdominal fetal echocardiography. Lancet. 1998;351:1023-27.
  204. Accuracy and limitations of transabdominal fetal echocardiography at 12-15 weeks of gestation in a population at high risk for congenital heart disease. Br J Obstet Gynaecol. 2000;16:30-36.
  205. Increased first trimester nuchal translucency as a prenatal manifestation of Smith-Lemli- Opitz syndrome. Am J Med Genet. 1995;58:374-76.
  206. Nuchal thickening or cystic hygromas in first- and second- trimester fetuses: Prognosis and outcome. Obstet Gynecol. 1993;82:43-48.
  207. Outcome of chromosomally normal livebirths with increased fetal nuchal translucency at 10-14 weeks’ gestation. J Med Genet 1998; 35:222-24.
  208. Increased firsttrimester nuchal translucency: Pregnancy and infant outcomes after routine screening for Down's syndrome in an unselected antenatal population. Br J Radiol. 1999;72:457-60.
  209. Pregnancy outcome and infant follow-up of fetuses with abnormally increased first trimester nuchal translucency. Hum Reprod 2000;15:2023-27.
  210. Fetal nuchal translucency and normal chromosomes: A long-term follow-up study. Ultrasound Obstet Gynecol. 2001;18:18-22.
  211. Inadequate maternal vascular response to placentation in pregnancies complicated by preeclampsia and by small-for-gestational age infants. Brit J Obstet Gynaecol. 1986;93:1049-59.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.